[DigitalToday reporter Chi-gyu Hwang] Yuanta Securities said in a report on Sunday that HectoInnovation’s second-quarter results showed growth in both its core business and consolidated subsidiaries. It said it expects the company’s shares to show a different pattern if it fleshes out a stablecoin business that could serve as a growth trigger.

HectoInnovation posted second-quarter revenue of 102.83 billion won and operating profit of 12.88 billion won, up 12.0 percent and down 4.0 percent from a year earlier, respectively.

Kwon Myung-joon (권명준), an analyst at Yuanta Securities, said consolidated revenue exceeded 100 billion won for a second straight quarter. He said it was likely the company would continue to deliver quarterly revenue of more than 100 billion won, even though fintech performance slowed in the second quarter of this year.

On HectoHealthcare, it said quarterly revenue has continued at more than 20 billion won since the second quarter of 2025. It said this could be interpreted as meaning the popularity of key products such as Desimone is sustained rather than temporary.

Yuanta Securities also highlighted the stablecoin business. It said that on July 15 the Financial Services Commission said it would institutionalise issuance and distribution systems for stablecoins used as new means of payment in major countries, and said it would also prepare a Digital Asset Act as part of measures to innovate financial services. It said HectoInnovation is working to build a stablecoin ecosystem linked to its subsidiaries and plans to provide a stablecoin payment solution by combining HectoWalletOne wallet technology with payment infrastructure at its subsidiary HectoFinancial.

It added that HectoWalletOne is the company that has carried out the most wallet commercialisation among virtual asset service providers with blockchain wallet infrastructure technology. It said it believed conditions were in place for the business to stand out in the market.

Park Jong-seon (박종선), an analyst at Eugene Investment & Securities, also said in a second-quarter results review report that HectoInnovation has continued to maintain year-on-year quarterly revenue growth. He said second-quarter revenue, like the previous quarter, reached the 100 billion won range, sustaining its growth trend.

Eugene Investment & Securities said it expects revenue growth at HectoHealthcare as the effects of expanding new product lineups, such as broadening the skincare line of inner beauty brand Onlytual, and diversifying distribution channels continue. It also said the company plans to launch related new products early next year after receiving individual certification from the Ministry of Food and Drug Safety for functionality recognised as being able to help reduce body fat.